Interquim, S.A. v. Berg Imports LLC

CourtDistrict Court, E.D. Michigan
DecidedMarch 14, 2022
Docket3:21-cv-10665
StatusUnknown

This text of Interquim, S.A. v. Berg Imports LLC (Interquim, S.A. v. Berg Imports LLC) is published on Counsel Stack Legal Research, covering District Court, E.D. Michigan primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Interquim, S.A. v. Berg Imports LLC, (E.D. Mich. 2022).

Opinion

UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION ______________________________________________________________________

INTERQUIM, S.A.,

Plaintiff/Counter-Defendant,

v. Case No. 21-10665

BERG IMPORTS, LLC,

Defendant/Counter-Plaintiff/ Third-Party Plaintiff,

v.

GRUPO FERRER INTERNACIONAL, S.A.,

Third-Party Defendant. ________________________________/

OPINION AND ORDER GRANTING INTERQUIM’S MOTION TO DISMISS AND GRANTING GRUPO FERRER INTERNACIONAL’S MOTION TO DISMISS

Plaintiff Interquim, S.A. is a Spanish corporation that develops, manufactures, and markets dietary and nutritional supplements and other pharmaceutical products. Interquim brings this action against Berg Imports, LLC for breach of contract, common law conversion, and statutory conversion under Michigan law. (ECF No. 1, PageID.6-9.) According to Interquim, Berg breached an oral distribution agreement under which Berg acted as the United States distributor of a particular product. (ECF No. 1, PageID.1-2.) Berg filed a counterclaim against Interquim for breach of contract (ECF No. 13, PageID.66-78) and a third-party complaint against Interquim’s parent company, Grupo Ferrer Internacional, S.A., for tortious interference with contract and civil conspiracy. (ECF No. 14, PageID.94-96.) Before the court are Interquim’s (ECF No. 19) and Grupo Ferrer’s (ECF No. 20) motions to dismiss claims brought by Berg. The matters have been fully briefed (ECF Nos. 23, 24, 26, 27, 28, 29), and the court does not find a hearing to be necessary. E.D. Mich. LR 7.1(f)(2). For the reasons stated below, the court will grant both motions.

I. BACKGROUND The following facts are either alleged in Plaintiff’s complaint or agreed upon by the parties. In a motion to dismiss, the court accepts Plaintiff’s factual allegations as true but makes no overt finding as to truth or falsity. Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). Grupo Ferrer is a multinational biotechnology company that manufactures and sells various pharmaceutical and dietary products, including citicoline. (ECF No. 13, PageID.68.) Citicoline is a dietary supplement that is used for, inter alia, its “neuroprotective properties that can enhance or improve attention, focus and recall.” (Id., PageID.67.) In approximately 2014, Interquim, Grupo Ferrer’s wholly owned

subsidiary, began manufacturing and selling citicoline under the brand name Xerenoos. (Id., PageID.68.) In 2014, Interquim and Berg entered into an oral distribution agreement, whereby Berg would serve as the “exclusive distributor of Xerenoos in the United States.” (Id., PageID.69.) Under the distribution agreement, “Berg would attempt to build a market for Xerenoos in the United States,” and Berg maintains that “the parties recognized that significant resources would have to be expended by Berg in order for this new product to penetrate the U.S. market.” (Id.) The contract, according to Berg, “necessarily was a long-term arrangement” and that the parties understood “it would take Berg years to ramp-up the business, develop a market for Xerenoos and launch the product,” particularly during a “Startup Period.” (Id., PageID.69-70.) Berg expended significant resources in their efforts to distribute Xerenoos during the Startup Period, which occurred between 2014 and 2016. (Id., PageID.70.) The terms of the parties’ contract

were simple: under the distribution agreement, Interquim provided Xerenoos to Berg, and Berg was paid on a commission basis, earning 5% on all Xerenoos sales in the United States. (Id., PageID.69-70.) Grupo Ferrer utilizes additional suppliers of citicoline in its global business endeavors. (Id., PageID.68.) Its largest supplier of citicoline for sale outside of the United States is a biotechnology company called Kyowa Hakko Bio Co., based in Tokyo, Japan. (Id.) Kyowa Hakko, through a subsidiary, also sells citicoline in the United States under the brand name Cognizin. (Id.) Thus, Grupo Ferrer was “competing with Kyowa Hakko with the sale of Xerenoos in the United States through its subsidiary, Interquim,” while at the same time “partnering with Kyowa Hakko by acquiring citicoline

from it for sale outside the United States.” (Id.) According to Berg, Kyowa Hakko commenced “an intimidation and misinformation campaign against Xerenoos” in order to prevent Xerenoos “from gaining a foothold in the United States.” (Id., PageID.70) This included accusing Berg of failing to disclose the presence of “unapproved” ingredients in Xerenoos and posting a public article that made false statements about the chemical structure of Xerenoos. (Id.) Furthermore, Kyowa Hakko allegedly “continuously pressured [Grupo] Ferrer to quash the U.S. distribution of Xerenoos to reduce competition.” (Id.) However, despite these obstacles, Berg “began realizing meaningful profits derived from its commission earnings” under the distribution agreement. (Id, PageID.71.) Between 2017 and 2019, Berg’s revenues were $364,065, $465,985, and $920,558, respectively. (Id.) Interquim expressed no serious concerns with Berg’s performance during this time period, nor did it indicate any intention of terminating the parties’ agreement if sales did not improve.

(Id., PageID.72.) In July 2019, Interquim began transferring its business activity to a new entity, HealthTech BioActives “as part of a spin-off of Interquim” into HealthTech BioActives. (Id., PageID.73.) Interquim, however, continued to oversee Xerenoos. (Id.) Interquim did not inform Berg of any changes to their distribution agreement until January 13, 2020, when Interquim informed Berg that it would cease providing Berg with citicoline for sale in the United States. (Id.) No “notice” or “commercial justification” was given to Berg, and Interquim asked Berg to “account for and return its remaining citicoline inventory to Interquim.” (Id.) Pointing to the lack of advance notice and commercial justification, Berg

maintains that the contract was terminated in bad faith. (Id., PageID.74-76.) Consequently, it decided to satisfy existing orders in 2020 for Xerenoos for $727,200, and it further sold its remaining inventory of Xerenoos for $619,760.55. (Id., PageID.74.) These amounts were retained “as a partial set-off against the monetary damages” suffered by the termination of the distribution agreement. (Id.) Berg alleges that Interquim’s termination was in bad faith because “Kyowa Hakko pressured Ferrer and Interquim” so that Cognizin could dominate the United States citicoline market. (Id., PageID.75.) As to Grupo Ferrer, Berg argues “in order to maintain its supply relationship with Kyowa Hakko for the sale of citicoline outside the United States, [Grupo] Ferrer bowed to pressure exerted by Kyowa Hakko and colluded with Interquim to exit the U.S. market by discontinuing the supply of citicoline to Berg” and terminating the distribution agreement between Interquim and Berg. (Id.) And although Interquim maintains that “Xerenoos sales did not meet projections or expectations,” Berg claims that this

justification for termination was a pretext for an “anti-competitive arrangement between [Grupo] Ferrer and Kyowa Hakko.” (Id.) Interquim filed an action on March 26, 2021, bringing breach of contract and conversion claims against Berg for wrongfully retaining Xerenoos inventory and withholding profit on its sales; it has demanded payment, “minus a 5% commission for Berg” that it is still willing to pay. (ECF No. 1, PageID.5-9.) In its answer, Berg brought a counterclaim against Interquim for breach of contract1 (ECF No. 13, PageID.66-78) and also filed a third-party complaint against Grupo Ferrer for tortious interference with contract and civil conspiracy. (ECF No. 14, PageID.94-96.)

II.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Tellabs, Inc. v. Makor Issues & Rights, Ltd.
551 U.S. 308 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Busam Motor Sales v. Ford Motor Co.
203 F.2d 469 (Sixth Circuit, 1953)
Cloverdale Equipment Company v. Simon Aerials, Inc.
869 F.2d 934 (Sixth Circuit, 1989)
General Aviation, Inc. v. The Cessna Aircraft Co.
915 F.2d 1038 (Sixth Circuit, 1990)
Karen Stephenson v. Allstate Insurance Company
328 F.3d 822 (Sixth Circuit, 2003)
Bassett v. National Collegiate Athletic Ass'n
528 F.3d 426 (Sixth Circuit, 2008)
Hensley Manufacturing, Inc. v. Propride, Inc.
579 F.3d 603 (Sixth Circuit, 2009)
Bushwick-Decatur Motors, Inc. v. Ford Motor Co.
116 F.2d 675 (Second Circuit, 1940)
Advocacy Organization for Patients & Providers v. Auto Club Insurance
670 N.W.2d 569 (Michigan Court of Appeals, 2003)
Lichnovsky v. Ziebart International Corp.
324 N.W.2d 732 (Michigan Supreme Court, 1982)
Dzierwa v. Michigan Oil Co.
393 N.W.2d 610 (Michigan Court of Appeals, 1986)
Early Detection Center, PC v. New York Life Insurance
403 N.W.2d 830 (Michigan Court of Appeals, 1986)
Health Call of Detroit v. Atrium Home & Health Care Services, Inc
706 N.W.2d 843 (Michigan Court of Appeals, 2005)
Dunn v. Goebel Brewing Co.
99 N.W.2d 380 (Michigan Supreme Court, 1959)

Cite This Page — Counsel Stack

Bluebook (online)
Interquim, S.A. v. Berg Imports LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/interquim-sa-v-berg-imports-llc-mied-2022.